Mania and Bipolar-Related Concerns

Urgent help first

Mania can bring little sleep, racing thoughts, risky decisions and loss of judgment. If someone is in danger, call 911 in the US. For suicidal thoughts, call or text 988 (US Suicide & Crisis Lifeline). For a seizure, severe confusion or a possible poisoning, call 911 or Poison Help at 1-800-222-1222. This page is education only. Never stop or change a prescribed medicine because of anything here; talk with the prescriber.

Why bipolar disorder matters here

Bipolar disorder involves episodes of depression and of mania (a period of unusually high energy, mood and activity) or hypomania (a milder form). Psychedelics change mood and arousal, so researchers ask whether they can trigger mania, especially in people with bipolar disorder or a family history of it. Evidence labels used: established, mixed, insufficient evidence, evidence of harm.

What the sources report

Systematic review and meta-analysis (2026). A review of 23 human studies of psilocybin, LSD, mescaline, DMT/ayahuasca and MDMA, with four in the meta-analysis, looked at mood-elevation outcomes. Reported rates of dysphoria or euphoria, hypomania or mania ranged from 5.8% in controlled trials of psilocybin-assisted therapy for major depression to 30% in naturalistic studies of people with bipolar disorder. When manic symptoms occurred they were typically acute and self-limited. Observational studies found higher risk in people with bipolar I disorder, family vulnerability, polysubstance use, and unsupervised or illegal use. In registry cohorts, 4% (95% confidence interval 2% to 8%, 7,478 people) later received a bipolar diagnosis, with little evidence of a signal specific to hallucinogens. The authors conclude the risk of transient mood-related symptoms is low but clinically meaningful in susceptible people, that psychedelics appear relatively safe in controlled clinical settings, and that long-term outcomes and repeated exposure are insufficiently studied. [1] Label: mixed; insufficient evidence for long-term outcomes.

The rates are not comparable across study types: the 5.8% and 30% figures combine different outcomes and very different groups of people, so they should not be read as one risk.

Trial exclusions. NIDA says participants with previously diagnosed psychosis or bipolar disorder, and sometimes other mental illnesses, are excluded from modern psychedelic research as a precaution. [2] A 2024 review notes that most modern psilocybin trials have excluded people with a family history of bipolar disorder, and argues for a risk-stratified approach rather than blanket exclusion; this is the authors' proposal, and it relies on case studies and surveys because trial data are missing. [3]

Lithium and other mood stabilizers. In an analysis of online experience reports (not clinical data), 47% of 62 reports of classic psychedelics taken with lithium involved seizures, compared with none of 34 reports involving lamotrigine. The authors provisionally concluded that psychedelic use may pose a significant seizure risk for people on lithium. [4] These are unverified self-reports, so the true rate is unknown. Label: evidence of harm (reports), insufficient evidence for rates. See psychedelic drug interactions and toxicology.

Esketamine. The US Medication Guide lists an extreme increase in activity and talking (mania) among changes in mood or behavior to report to a health care provider. [5] No separate bipolar trial data for ketamine or esketamine were read for this page.

What is not known

• Proper evidence not found for the effect of any single psychedelic on bipolar disorder in randomized trials, because such trials have excluded these participants. What exists is observational.
• Long-term risk after repeated exposure is not established. [1]
• Findings for psilocybin do not transfer to LSD, MDMA or other substances without checking each one.

Who should talk with a clinician first

People with bipolar disorder or a close relative with it, and anyone with a history of mania, should discuss any interest in these substances, including research participation, with a clinician. See talking with a health professional. Related pages: psychosis vulnerability, screening and eligibility in clinical research and psychedelic adverse effects and contraindications.